查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1580912

胞外体诊断和治疗市场：按产品、应用和最终用户划分 - 全球预测 2025-2030

Exosome Diagnostics & Therapeutics Market by Product (Instrument, Reagent, Software), Application (Diagnostic, Therapeutic), End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年胞外体诊断与治疗市值为8.5108亿美元，预计2024年将达到10.2904亿美元，复合年增长率为21.27%，到2030年将达到32.841亿美元，预计将达到1000万美元。

胞外体诊断和治疗是生物医学研究的一个创新前沿，其特点是探索称为胞外体的微小细胞外囊泡，其在疾病诊断和治疗中具有巨大的应用潜力。这些囊泡促进细胞间通讯和运输蛋白质和 RNA 等分子。该领域的需求源于能够实现癌症、神经退化性疾病和心臟病等微创诊断技术的能力。胞外体具有广泛的用途，包括疾病监测、生物标记发现和标靶药物递送，并具有多种最终用途领域，包括医学研究机构、医院和生物製药公司。该市场的推动因素包括研究经费的增加、胞外体分离和表征的技术进步以及对个人化医疗的日益关注。

主要市场统计
基准年[2023] 85108万美元
预测年份 [2024] 1,029,040,000 美元
预测年份 [2030] 32.841 亿美元
复合年增长率（%） 21.27%

主要成长动力包括慢性病的流行、液态切片的日益普及以及对创新诊断工具的需求。然而，技术成本高、标准化不足和监管障碍高等挑战阻碍了市场扩张。儘管存在这些障碍，但新的商机仍然存在，包括相关人员之间加强合作以加强产品平臺，以及对更有效的胞外体分离和表征方法的​​研发投资增加。企业应专注于建立策略伙伴关係并开发具有成本效益的解决方案以克服经济限制。

持续的创新可能会围绕着提高基于胞外体的检测和用于治疗目的的递送机制的准确性进行。个人化医疗，特别是强调客製化胞外体为基础的治疗方法以满足个别患者的需求，提供了一条有希望的成长途径。市场的本质是竞争性的且不断发展，新参与企业和现有企业都在寻求开拓新颖的解决方案。寻求发展的公司还应该考虑开拓有利的区域市场和有利的医疗保健政策，并制定教育倡议，以提高医疗保健专业人员和广大患者对外胞外体技术的认识和接受度。

市场动态：快速发展的胞外体诊断和治疗市场的关键市场洞察

由于供需之间的动态交互作用，胞外体诊断和治疗药物市场正在经历转型。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 癌症和其他慢性疾病的盛行率上升
    • 政府加大努力和宣传活动以提高意识
    • 扩大胞外体为基础的诊断和治疗药物在神经系统疾病治疗的应用
  • 市场限制因素
    • 进行基于胞外体的诊断的成本高且程序复杂
  • 市场机会
    • 针对个别患者量身定制个人化医疗的趋势不断增长
    • 非侵入性诊断工具技术开发
  • 市场挑战
    • 与胞外体分离、表征和分析标准化通讯协定相关的问题

波特的五力：开拓胞外体诊断与治疗市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解外部胞外体诊断和治疗药物市场的影响

外部宏观环境因素在塑造胞外体诊断和治疗市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解胞外体诊断和治疗药物市场的竞争状况

胞外体诊断和治疗市场的详细市场占有率分析提供了对供应商绩效的全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵胞外体诊断与治疗市场供应商的绩效评估

FPNV定位矩阵是评估胞外体诊断和治疗市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议 规划胞外体诊断与治疗市场的成功之路

胞外体诊断和治疗市场的策略分析对于旨在加强其在全球市场的影响力的公司至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：全面分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监管核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 癌症和其他慢性疾病的发生率上升
      • 加强政府措施及宣传宣传活动
      • 扩大胞外体诊断与治疗在神经系统疾病治疗的应用
    • 抑制因素
      • 进行基于胞外体的诊断的高成本且程序复杂
    • 机会
      • 针对个别患者的个人化医疗的扩展趋势
      • 非侵入性诊断工具技术开发
    • 任务
      • 与胞外体分离、表征和分析标准化通讯协定相关的问题
  • 市场区隔分析
    • 产品：资料库管理系统增加了软体胞外体诊断和治疗中的使用
    • 应用：透过组织修復和再生实现胞外体诊断和治疗的新应用
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章胞外体诊断与治疗市场：副产品

  • 装置
  • 试剂
  • 软体

第七章胞外体诊断与治疗药物市场：依应用分类

  • 诊断
  • 治疗性的

第 8 章胞外体诊断与治疗市场：依最终使用者分类

  • 癌症研究所
  • 诊断中心
  • 医院

第九章 北美和南美胞外体诊断和治疗药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章 亚太地区胞外体诊断与治疗药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章 欧洲、中东和非洲的胞外体诊断与治疗药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • Promega 和 INOVIQ 合作透过先进的胞外体生物标记解决方案彻底改变癌症研究
    • Lonza Group AG 与 Neurosense Therapeutics 合作，利用细胞外囊泡专业知识加强神经退化性疾病研究
    • FUJIFILM Holdings控股公司推出 MassivEV 技术，可提高治疗和诊断的纯度、扩充性和效率
  • 战略分析和建议

公司名单

  • AEGLE Therapeutics
  • AMS Biotechnology
  • Bio-Techne Corporation
  • Capital Biosciences, Inc.
  • Capricor Therapeutics, Inc.
  • CUREXSYS GMBH IL
  • Direct Biologics LLC
  • Everzom
  • Evox Therapeutics Limited
  • EXOGENUS THERAPEUTICS, SA
  • ILIAS Biologics Inc.
  • KIMERA LABS
  • Lonza Group AG
  • Mercy Bioanalytics
  • NanoFCM Co., Ltd
  • NanoSomiX, Inc.
  • NeuroSense Therapeutics Ltd.
  • Promega Corporation
  • RION
  • Sienna Cancer Diagnostics Ltd
  • System Biosciences, LLC.
Product Code: MRR-4F7B2F382F30

The Exosome Diagnostics & Therapeutics Market was valued at USD 851.08 million in 2023, expected to reach USD 1,029.04 million in 2024, and is projected to grow at a CAGR of 21.27%, to USD 3,284.10 million by 2030.

Exosome diagnostics and therapeutics represent an innovative frontline in biomedical research, characterized by the exploration of exosomes, small extracellular vesicles with significant potential in disease diagnosis and therapeutic applications. These vesicles facilitate intercellular communication and carry molecules such as proteins and RNA, crucial for regulating pathological and physiological processes. The necessity of this field arises from its capacity to enable minimally invasive diagnostic techniques, particularly for cancer, neurodegenerative diseases, and cardiac conditions. Exosome applications extend widely across disease monitoring, biomarker discovery, and targeted drug delivery, with diverse end-use sectors including medical research institutes, hospitals, and biopharmaceutical companies. The market is propelled by increased funding for research, technological advancements in exosome isolation and characterization, and a growing focus on personalized medicine.

KEY MARKET STATISTICS
Base Year [2023] USD 851.08 million
Estimated Year [2024] USD 1,029.04 million
Forecast Year [2030] USD 3,284.10 million
CAGR (%) 21.27%

Key growth drivers include the escalating prevalence of chronic diseases, heightened adoption of liquid biopsies, and the demand for innovative diagnostic tools. However, challenges such as the high cost of technology, insufficient standardization, and significant regulatory hurdles impede market expansion. Despite these obstacles, emerging opportunities lie in expanding collaborations among stakeholders to enhance product pipelines and increase investment in R&D for more efficient exosome isolation and characterization methods. Businesses should focus on forming strategic partnerships and developing cost-effective solutions to overcome economic limitations.

Continued innovation could revolve around the precision of exosome-based assays and improving delivery mechanisms for therapeutic purposes. Emphasizing personalized medicine, notably the customization of exosome-based therapies to meet individual patient needs, offers a promising avenue for growth. In terms of market nature, it is competitive and continually evolving as new entrants and existing players strive to pioneer novel solutions. Companies seeking growth should also consider tapping into lucrative regional markets with favorable healthcare policies and establishing educational initiatives to enhance awareness and acceptance of exosome technology across healthcare professionals and patients.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Exosome Diagnostics & Therapeutics Market

The Exosome Diagnostics & Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of cases of cancer and other chronic illnesses
    • Increasing government initiatives and campaigns for awareness
    • Expanding applications of exosome-based diagnostics and therapeutics in neurological disorders treatment
  • Market Restraints
    • High costs and complex procedures for implementing exosome-based diagnostics
  • Market Opportunities
    • Growing trend of personalized medicine tailored to individual patients
    • Technological development of non-invasive diagnostic tools
  • Market Challenges
    • Issues associated with standardized protocols for exosome isolation, characterization, and analysis

Porter's Five Forces: A Strategic Tool for Navigating the Exosome Diagnostics & Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Exosome Diagnostics & Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Exosome Diagnostics & Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Exosome Diagnostics & Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Exosome Diagnostics & Therapeutics Market

A detailed market share analysis in the Exosome Diagnostics & Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Exosome Diagnostics & Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Exosome Diagnostics & Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Exosome Diagnostics & Therapeutics Market

A strategic analysis of the Exosome Diagnostics & Therapeutics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Exosome Diagnostics & Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AEGLE Therapeutics, AMS Biotechnology, Bio-Techne Corporation, Capital Biosciences, Inc., Capricor Therapeutics, Inc., CUREXSYS GMBH IL, Direct Biologics LLC, Everzom, Evox Therapeutics Limited, EXOGENUS THERAPEUTICS, S.A., ILIAS Biologics Inc., KIMERA LABS, Lonza Group AG, Mercy Bioanalytics, NanoFCM Co., Ltd, NanoSomiX, Inc., NeuroSense Therapeutics Ltd., Promega Corporation, RION, Sienna Cancer Diagnostics Ltd, and System Biosciences, LLC..

Market Segmentation & Coverage

This research report categorizes the Exosome Diagnostics & Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Instrument, Reagent, and Software.
  • Based on Application, market is studied across Diagnostic and Therapeutic.
  • Based on End User, market is studied across Cancer Institute, Diagnostic Center, and Hospital.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of cases of cancer and other chronic illnesses
      • 5.1.1.2. Increasing government initiatives and campaigns for awareness
      • 5.1.1.3. Expanding applications of exosome-based diagnostics and therapeutics in neurological disorders treatment
    • 5.1.2. Restraints
      • 5.1.2.1. High costs and complex procedures for implementing exosome-based diagnostics
    • 5.1.3. Opportunities
      • 5.1.3.1. Growing trend of personalized medicine tailored to individual patients
      • 5.1.3.2. Technological development of non-invasive diagnostic tools
    • 5.1.4. Challenges
      • 5.1.4.1. Issues associated with standardized protocols for exosome isolation, characterization, and analysis
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product: Rising use of software in exosome diagnostics and therapeutics owing to database management systems
    • 5.2.2. Application: Emerging applications of exosome diagnostics and therapeutics due to tissue repair and regeneration
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Exosome Diagnostics & Therapeutics Market, by Product

  • 6.1. Introduction
  • 6.2. Instrument
  • 6.3. Reagent
  • 6.4. Software

7. Exosome Diagnostics & Therapeutics Market, by Application

  • 7.1. Introduction
  • 7.2. Diagnostic
  • 7.3. Therapeutic

8. Exosome Diagnostics & Therapeutics Market, by End User

  • 8.1. Introduction
  • 8.2. Cancer Institute
  • 8.3. Diagnostic Center
  • 8.4. Hospital

9. Americas Exosome Diagnostics & Therapeutics Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Exosome Diagnostics & Therapeutics Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Exosome Diagnostics & Therapeutics Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Promega Corporation and INOVIQ Ltd. Forged an Alliance to Revolutionize Cancer Research with Advanced Exosome Biomarker Solutions
    • 12.3.2. Lonza Group AG and NeuroSense Therapeutics Forged Alliance to Enhance Neurodegenerative Disease Research Using Extracellular Vesicle Expertise
    • 12.3.3. Fujifilm Holdings Corporation Unveiled MassivEV Technology for High-Purity, Scalable, and Efficient Applications in Therapeutics and Diagnostics
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AEGLE Therapeutics
  • 2. AMS Biotechnology
  • 3. Bio-Techne Corporation
  • 4. Capital Biosciences, Inc.
  • 5. Capricor Therapeutics, Inc.
  • 6. CUREXSYS GMBH IL
  • 7. Direct Biologics LLC
  • 8. Everzom
  • 9. Evox Therapeutics Limited
  • 10. EXOGENUS THERAPEUTICS, S.A.
  • 11. ILIAS Biologics Inc.
  • 12. KIMERA LABS
  • 13. Lonza Group AG
  • 14. Mercy Bioanalytics
  • 15. NanoFCM Co., Ltd
  • 16. NanoSomiX, Inc.
  • 17. NeuroSense Therapeutics Ltd.
  • 18. Promega Corporation
  • 19. RION
  • 20. Sienna Cancer Diagnostics Ltd
  • 21. System Biosciences, LLC.

LIST OF FIGURES

  • FIGURE 1. EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INSTRUMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY REAGENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CANCER INSTITUTE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC CENTER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 25. BRAZIL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 28. CANADA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 31. MEXICO EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 38. ASIA-PACIFIC EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 42. AUSTRALIA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 45. CHINA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 48. INDIA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 51. INDONESIA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 54. JAPAN EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 57. MALAYSIA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 60. PHILIPPINES EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 63. SINGAPORE EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 66. SOUTH KOREA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 69. TAIWAN EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 72. THAILAND EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 75. VIETNAM EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 82. DENMARK EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 85. EGYPT EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 88. FINLAND EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 91. FRANCE EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 94. GERMANY EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 97. ISRAEL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 100. ITALY EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 103. NETHERLANDS EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 106. NIGERIA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 109. NORWAY EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 112. POLAND EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 115. QATAR EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 118. RUSSIA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 121. SAUDI ARABIA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH AFRICA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 127. SPAIN EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 130. SWEDEN EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 133. SWITZERLAND EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 136. TURKEY EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 139. UNITED ARAB EMIRATES EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED KINGDOM EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 145. EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 146. EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023